Developer docs
API playgroundTry for free, no card

Search company profiles

MCRA Holdings Inc.

Full company profile

uuid00ypr88

Namestring
MCRA Holdings Inc.
Legal namestring
MCRA, LLC
Websiteurl
mcra.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

MCRA Holdings Inc. (operating as MCRA, LLC and doing business as MCRA, an IQVIA business) is a Washington, DC-headquartered Clinical Research Organization (CRO) and advisory firm founded in 2004 by Viscogliosi Brothers, LLC. The company is purpose-built for the medical device, diagnostics, and biologics industry, integrating six "business value creators" — regulatory affairs, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics — into a single delivery model that takes MedTech clients from innovation conception through global commercialization. MCRA reports working with more than 850 MedTech companies annually on over 1,700 projects, with active engagements spanning 14+ therapeutic specializations including orthopedics, spine, cardiovascular, neurology, biologics, wound care, imaging and robotics, digital health, in-vitro diagnostics, and cell and gene therapy.

MCRA's product surface comprises 14+ service lines, organized into core and specialized offerings. Core services include the Global CRO, FDA Regulatory, Europe Regulatory, Japan Regulatory (delivered via MCRA Japan), Reimbursement/Health Economics & Market Access (RHEMA), Quality Assurance, Healthcare Compliance, and Talent Solutions. Specialized services include the AI & Imaging Center, Cybersecurity Solutions for Medical Devices, Digital Health Program (covering SaMD/SiMD), Statistical Analysis, Biocompatibility, and Human Factors. The business model is professional services — fee-for-service consulting and project-based engagements delivered directly to enterprise MedTech clients — with no publicly disclosed pricing or contract terms. Distribution is direct enterprise sales via offices in Washington DC, Hartford CT, New York NY, and Tokyo, supported by content marketing, case studies, webinars, and a newsletter funnel.

The company is privately held and operates as a subsidiary of IQVIA (NYSE:IQV), the global life sciences analytics and CRO platform. In March 2022, MCRA acquired Vorpal Technologies K.K. (now MCRA Japan), a Tokyo-based MedTech consulting firm founded in 2013, establishing a regional headquarters in Japan with D-MAH services, shonin approvals expertise, and reimbursement category listings. Senior leadership includes David Lown (President), Samuel Pollard (General Manager, MCRA Japan), Alex Cadotte Ph.D. (VP, Digital Health/AI/Radiology Regulatory Affairs), and dedicated Directors across Digital Health, Cybersecurity, Clinical Affairs, and Imaging Operations.

Short descriptiontext

MCRA is a US-headquartered medical device CRO and advisory firm, integrating regulatory, clinical research, reimbursement, compliance, quality, and distribution services to support 850+ MedTech companies annually across the US, Europe, and Japan.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device CRO, regulatory consulting, clinical research services, reimbursement strategy, healthcare compliance advisory
Industry3 codes
1Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
CodeHLAGAAALPrimaryYes
2Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
CodeHLAGAKAIPrimaryNo
3Clinical CROs (Phase I–IV)
CodeHLAGAAAAPrimaryNo
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
  • Management Consulting Services54161
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Device CRO & Regulatory Consulting
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1CRO Services
TypeProfessional Services
Description

Global Clinical Research Organization services providing clinical trial operations and regulatory affairs support for medical devices, diagnostics, and biologics.

mcra.com
2Regulatory Consulting
TypeProfessional Services
Description

FDA Regulatory Consultant services, Europe Regulatory, Japan Regulatory Medical Device Consultants, and Global Regulatory services.

mcra.com
3Reimbursement Services
TypeProfessional Services
Description

Medical Device Reimbursement, Health Economics & Market Access (RHEMA) services.

mcra.com
4Quality Assurance & Healthcare Compliance
TypeProfessional Services
Description

Quality Assurance, Healthcare Compliance, Cybersecurity Solutions for Medical Devices services.

mcra.com
5Specialized Services
TypeProfessional Services
Description

Biocompatibility Services, Statistical Analysis for Medical Devices, Human Factors and Usability Engineering, Talent Solutions, and AI & Imaging Center services.

mcra.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MCRA is a full-service Clinical Research Organization (CRO) and advisory firm for medical device, diagnostics, and biologics companies, delivering integrated consulting across six business value creators: regulatory affairs, clinical research, reimbursement/health economics & market access, healthcare compliance, quality assurance, and distribution logistics. The firm guides clients from innovation conception through global commercialization, with particular depth in FDA, European, and Japanese regulatory pathways, including De Novo grants, 510(k) clearances, and Shonin approvals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than 850 MedTech companies served annually on more than 1700 projects
+2 more records
Product overview1 text field

MCRA Holdings Inc., an IQVIA business, operates as a leading medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm. The company offers integrated consulting services through its six core business value creators: regulatory affairs, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics. Key service offerings include Global Clinical Research Organization (CRO), FDA Regulatory Consultant, Europe Regulatory, Japan Regulatory Medical Device Consultants, Reimbursement Health Economics & Market Access (RHEMA), Quality Assurance, AI & Imaging Center, Talent Solutions, Cybersecurity Solutions, Digital Health Program, Statistical Analysis for Medical Devices, Biocompatibility Services, Healthcare Compliance, and Human Factors. MCRA works with more than 850 companies in the MedTech industry annually on more than 1700 projects. The company maintains offices in Washington, DC, Hartford, CT, New York, NY, and Tokyo, Japan.

Product and service14 records
1Global Clinical Research Organization (CRO)
CategoryClinical Research Services
Description

Full-service CRO offering clinical trial design, execution, and management for medical devices, diagnostics, and biologics across multiple therapeutic areas, intended for medical device manufacturers seeking clinical evidence for regulatory submissions.

2FDA Regulatory Consultant
3Europe Regulatory
4Japan Regulatory Medical Device Consultants
CategoryRegulatory Affairs
Description

Regulatory and clinical consulting for Japan market entry, including Shonin approvals and reimbursement strategy, delivered through MCRA Japan (Vorpal Technologies K.K.).

5Reimbursement, Health Economics & Market Access (RHEMA)
6Quality Assurance
7AI & Imaging Center
8Talent Solutions
9Cybersecurity Solutions for Medical Devices
10Digital Health Program
11Statistical Analysis for Medical Devices
12Biocompatibility Services
13Healthcare Compliance
14Human Factors and Usability Engineering
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Acquired in March 2022, Vorpal is the premier MedTech consulting firm for Japan and leader in new regulatory approvals. Founded in 2013 and headquartered in Tokyo, Vorpal is a full-service virtual subsidiary enabling international MedTech innovators to enter the Japanese market. MCRA announced Samuel Pollard as General Manager of Vorpal following the acquisition.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is MCRA's parent company and one of the largest global CROs; its broader life sciences clinical and technology platforms both support and compete with MCRA's specialty device franchise within the same corporate portfolio.

TypeDirect peer
Description

Premier Research operates a dedicated MedTech and specialty CRO practice with regulatory, clinical, and reimbursement services for medical device and diagnostic sponsors. It overlaps directly with MCRA across device regulatory strategy and clinical trial execution.

TypeDirect peer
Description

NAMSA is the largest independent medical device-focused CRO, providing regulatory, clinical, and laboratory services to MedTech companies globally. It is the closest direct competitor to MCRA across the same device-focused regulatory and clinical value chain.

TypeEmerging player
Description

Worldwide Clinical Trials is a mid-sized CRO with growing medical device and rare disease focus, providing clinical and regulatory services that overlap with MCRA's device-focused offering.

TypeEmerging player
Description

RCRI is a smaller, MedTech-specialized CRO offering regulatory affairs, clinical trial management, and quality services to medical device companies. It is a comparable niche competitor to MCRA in the device regulatory space.

TypeEmerging player
Description

BBA is a boutique MedTech-focused CRO providing clinical operations, regulatory affairs, and quality assurance to device companies. It competes with MCRA in the same specialty CRO segment, particularly for smaller device sponsors.

TypeBroad incumbent
Description

Charles River is a large CRO/CDMO with a growing medical device and diagnostics practice, including preclinical and clinical research services. It competes with MCRA for device sponsors seeking integrated research support.

TypeOthers
Description

Veeva provides cloud-based software (Vault) for regulatory, clinical, and quality operations in life sciences, including MedTech. It is an enabling technology partner/adjacent competitor to MCRA's regulatory and QA services rather than a direct CRO.

TypeBroad incumbent
Description

Medpace is a mid-to-large global CRO with a growing medical device and diagnostics franchise alongside its core biopharma business. It competes with MCRA on device clinical trials while offering much broader scale and full-service capabilities.

TypeBroad incumbent
Description

Parexel is a global full-service CRO with significant medical device experience and regulatory consulting capabilities, competing with MCRA for device sponsor engagements across clinical and regulatory phases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MCRA Holdings Inc.

Medical Device CRO & Regulatory Consultingmcra.com

MCRA is a US-headquartered medical device CRO and advisory firm, integrating regulatory, clinical research, reimbursement, compliance, quality, and distribution services to support 850+ MedTech companies annually across the US, Europe, and Japan.

What MCRA Holdings Inc. does

MCRA Holdings Inc. (operating as MCRA, LLC and doing business as MCRA, an IQVIA business) is a Washington, DC-headquartered Clinical Research Organization (CRO) and advisory firm founded in 2004 by Viscogliosi Brothers, LLC. The company is purpose-built for the medical device, diagnostics, and biologics industry, integrating six "business value creators" — regulatory affairs, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics — into a single delivery model that takes MedTech clients from innovation conception through global commercialization. MCRA reports working with more than 850 MedTech companies annually on over 1,700 projects, with active engagements spanning 14+ therapeutic specializations including orthopedics, spine, cardiovascular, neurology, biologics, wound care, imaging and robotics, digital health, in-vitro diagnostics, and cell and gene therapy.

MCRA's product surface comprises 14+ service lines, organized into core and specialized offerings. Core services include the Global CRO, FDA Regulatory, Europe Regulatory, Japan Regulatory (delivered via MCRA Japan), Reimbursement/Health Economics & Market Access (RHEMA), Quality Assurance, Healthcare Compliance, and Talent Solutions. Specialized services include the AI & Imaging Center, Cybersecurity Solutions for Medical Devices, Digital Health Program (covering SaMD/SiMD), Statistical Analysis, Biocompatibility, and Human Factors. The business model is professional services — fee-for-service consulting and project-based engagements delivered directly to enterprise MedTech clients — with no publicly disclosed pricing or contract terms. Distribution is direct enterprise sales via offices in Washington DC, Hartford CT, New York NY, and Tokyo, supported by content marketing, case studies, webinars, and a newsletter funnel.

The company is privately held and operates as a subsidiary of IQVIA (NYSE:IQV), the global life sciences analytics and CRO platform. In March 2022, MCRA acquired Vorpal Technologies K.K. (now MCRA Japan), a Tokyo-based MedTech consulting firm founded in 2013, establishing a regional headquarters in Japan with D-MAH services, shonin approvals expertise, and reimbursement category listings. Senior leadership includes David Lown (President), Samuel Pollard (General Manager, MCRA Japan), Alex Cadotte Ph.D. (VP, Digital Health/AI/Radiology Regulatory Affairs), and dedicated Directors across Digital Health, Cybersecurity, Clinical Affairs, and Imaging Operations.

MCRA Holdings Inc. firmographics

Firmographics
Name
MCRA Holdings Inc.
Legal name
MCRA, LLC
Website
https://mcra.com
Company type
Private
Founded year
2004
Operating status
Operating
Short description
MCRA is a US-headquartered medical device CRO and advisory firm, integrating regulatory, clinical research, reimbursement, compliance, quality, and distribution services to support 850+ MedTech companies annually across the US, Europe, and Japan.
Ownership category
akta.pro rank

MCRA Holdings Inc. industry classification

Industry
Product category
Medical Device CRO & Regulatory Consulting
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
akta.pro secondary industries
Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

  • Medical device CRO
  • Regulatory consulting
  • Clinical research services
  • Reimbursement strategy
  • Healthcare compliance advisory

Where MCRA Holdings Inc. is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices4 records

Markets served

MCRA Holdings Inc. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. CRO Services: Global Clinical Research Organization services providing clinical trial operations and regulatory affairs support for medical devices, diagnostics, and biologics.
  2. Regulatory Consulting: FDA Regulatory Consultant services, Europe Regulatory, Japan Regulatory Medical Device Consultants, and Global Regulatory services.
  3. Reimbursement Services: Medical Device Reimbursement, Health Economics & Market Access (RHEMA) services.
  4. Quality Assurance & Healthcare Compliance: Quality Assurance, Healthcare Compliance, Cybersecurity Solutions for Medical Devices services.
  5. Specialized Services: Biocompatibility Services, Statistical Analysis for Medical Devices, Human Factors and Usability Engineering, Talent Solutions, and AI & Imaging Center services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

MCRA Holdings Inc. product offering

Product offering

Core offering

MCRA is a full-service Clinical Research Organization (CRO) and advisory firm for medical device, diagnostics, and biologics companies, delivering integrated consulting across six business value creators: regulatory affairs, clinical research, reimbursement/health economics & market access, healthcare compliance, quality assurance, and distribution logistics. The firm guides clients from innovation conception through global commercialization, with particular depth in FDA, European, and Japanese regulatory pathways, including De Novo grants, 510(k) clearances, and Shonin approvals.

Product overview

MCRA Holdings Inc., an IQVIA business, operates as a leading medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm. The company offers integrated consulting services through its six core business value creators: regulatory affairs, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics. Key service offerings include Global Clinical Research Organization (CRO), FDA Regulatory Consultant, Europe Regulatory, Japan Regulatory Medical Device Consultants, Reimbursement Health Economics & Market Access (RHEMA), Quality Assurance, AI & Imaging Center, Talent Solutions, Cybersecurity Solutions, Digital Health Program, Statistical Analysis for Medical Devices, Biocompatibility Services, Healthcare Compliance, and Human Factors. MCRA works with more than 850 companies in the MedTech industry annually on more than 1700 projects. The company maintains offices in Washington, DC, Hartford, CT, New York, NY, and Tokyo, Japan.

Differentiator

Problem solved

Functional benefit

Products and services

  • Global Clinical Research Organization (CRO) Full-service CRO offering clinical trial design, execution, and management for medical devices, diagnostics, and biologics across multiple therapeutic areas, intended for medical device manufacturers seeking clinical evidence for regulatory submissions.
  • FDA Regulatory Consultant
  • Europe Regulatory
  • Japan Regulatory Medical Device Consultants Regulatory and clinical consulting for Japan market entry, including Shonin approvals and reimbursement strategy, delivered through MCRA Japan (Vorpal Technologies K.K.).
  • Reimbursement, Health Economics & Market Access (RHEMA)
  • Quality Assurance
  • AI & Imaging Center
  • Talent Solutions
  • Cybersecurity Solutions for Medical Devices
  • Digital Health Program
  • Statistical Analysis for Medical Devices
  • Biocompatibility Services
  • Healthcare Compliance
  • Human Factors and Usability Engineering

Quantifiable outcome

  • More than 850 MedTech companies served annually on more than 1700 projects
  • +2 more outcomes

Companies that use MCRA Holdings Inc.

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles3 records

MCRA Holdings Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

MCRA Holdings Inc. partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Vorpal Technologies K.K.coreOthersAcquired in March 2022, Vorpal is the premier MedTech consulting firm for Japan and leader in new regulatory approvals. Founded in 2013 and headquartered in Tokyo, Vorpal is a full-service virtual subsidiary enabling international MedTech innovators to enter the Japanese market. MCRA announced Samuel Pollard as General Manager of Vorpal following the acquisition.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

MCRA Holdings Inc. competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: IQVIA is MCRA's parent company and one of the largest global CROs; its broader life sciences clinical and technology platforms both support and compete with MCRA's specialty device franchise within the same corporate portfolio.
  • Charles River Laboratories: Charles River is a large CRO/CDMO with a growing medical device and diagnostics practice, including preclinical and clinical research services. It competes with MCRA for device sponsors seeking integrated research support.
  • Medpace: Medpace is a mid-to-large global CRO with a growing medical device and diagnostics franchise alongside its core biopharma business. It competes with MCRA on device clinical trials while offering much broader scale and full-service capabilities.
  • Parexel: Parexel is a global full-service CRO with significant medical device experience and regulatory consulting capabilities, competing with MCRA for device sponsor engagements across clinical and regulatory phases.

Direct peers

  • Premier Research: Premier Research operates a dedicated MedTech and specialty CRO practice with regulatory, clinical, and reimbursement services for medical device and diagnostic sponsors. It overlaps directly with MCRA across device regulatory strategy and clinical trial execution.
  • NAMSA: NAMSA is the largest independent medical device-focused CRO, providing regulatory, clinical, and laboratory services to MedTech companies globally. It is the closest direct competitor to MCRA across the same device-focused regulatory and clinical value chain.

Emerging players

  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with growing medical device and rare disease focus, providing clinical and regulatory services that overlap with MCRA's device-focused offering.
  • RCRI (Regulatory & Clinical Research Institute): RCRI is a smaller, MedTech-specialized CRO offering regulatory affairs, clinical trial management, and quality services to medical device companies. It is a comparable niche competitor to MCRA in the device regulatory space.
  • Boston Biomedical Associates (BBA): BBA is a boutique MedTech-focused CRO providing clinical operations, regulatory affairs, and quality assurance to device companies. It competes with MCRA in the same specialty CRO segment, particularly for smaller device sponsors.

Others

  • Veeva Systems: Veeva provides cloud-based software (Vault) for regulatory, clinical, and quality operations in life sciences, including MedTech. It is an enabling technology partner/adjacent competitor to MCRA's regulatory and QA services rather than a direct CRO.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

MCRA Holdings Inc. social profiles

Digital presence

MCRA Holdings Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MCRA Holdings Inc. leadership team

Management profile

Number of profiles

Profiles8 records

MCRA Holdings Inc. subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MCRA Holdings Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MCRA Holdings Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MCRA Holdings Inc.

What does MCRA Holdings Inc. do?

MCRA is a full-service Clinical Research Organization (CRO) and advisory firm for medical device, diagnostics, and biologics companies, delivering integrated consulting across six business value creators: regulatory affairs, clinical research, reimbursement/health economics & market access, healthcare compliance, quality assurance, and distribution logistics. The firm guides clients from innovation conception through global commercialization, with particular depth in FDA, European, and Japanese regulatory pathways, including De Novo grants, 510(k) clearances, and Shonin approvals.

Is MCRA Holdings Inc. a public or private company?

MCRA Holdings Inc. is a private company. It is classified as corporate owned and is currently operating.

When was MCRA Holdings Inc. founded?

MCRA Holdings Inc. was founded in 2004.

Where is MCRA Holdings Inc. based?

MCRA Holdings Inc. is headquartered in Washington, United States, in the North America region.

How does MCRA Holdings Inc. make money?

Five revenue lines are on record. CRO Services are the primary driver. The others are regulatory Consulting, reimbursement Services, quality Assurance & Healthcare Compliance and specialized Services.

Who are MCRA Holdings Inc.'s main competitors?

Broad incumbents on record are IQVIA, Charles River Laboratories, Medpace and Parexel. Direct peers are Premier Research and NAMSA. Emerging players are Worldwide Clinical Trials, RCRI (Regulatory & Clinical Research Institute) and Boston Biomedical Associates (BBA). Veeva Systems is listed as an others.

Does MCRA Holdings Inc. have an API?

No public API is recorded for MCRA Holdings Inc..

What industry is MCRA Holdings Inc. in?

MCRA Holdings Inc.'s product category is Medical Device CRO & Regulatory Consulting. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 5417 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNexsen Accelerates U.S. Diagnostics Market Entry with MCRA PartnershipNexsen Limited has partnered with U.S.-based clinical research organization MCRA to accelerate its entry into the U.S. diagnostics market, with the partnership focused on guiding FDA regulatory strategy and commercialization planning for Nexsen's GBS Rapid Sensor and Kidney Function Diagnostics products. The first FDA interaction for the GBS Rapid Sensor is expected in early 2026, with early international market access and sales targeted for the second half of 2026. MCRA will also advise on pricing, distribution, and market access strategies as Nexsen works to position itself as a global leader in rapid point-of-care diagnostic technology.McraIn-Vitro Diagnostic Device ConsultingMCRA is a consulting firm that provides regulatory, clinical, and reimbursement services to In-Vitro Diagnostic (IVD) device manufacturers. The company assists clients through the total product life cycle, including design, pre-market development, market approval, and post-market surveillance in regions such as the US and EU.PR NewswireMCRA Expands Its Medical Device Digital Health and Cybersecurity Franchise with the Hiring of Jason TugmanMCRA, LLC announced the hiring of Jason Tugman as Associate Director of Cybersecurity Risk Management and Strategy to expand its digital health and cybersecurity services. This strategic move aims to support the growing trend of medical device commercialization by providing expertise across the technology lifecycle, from FDA submissions to post-market cybersecurity assistance. The appointment reflects MCRA's commitment to addressing critical regulatory and security challenges in the healthcare sector.PR NewswireMCRA Strengthens Its Reimbursement, Health Economics, and Market Access Division with the Hiring of John D. McDermott, Jr., MBAMCRA, LLC has hired John D. McDermott, Jr., as Senior Director of Reimbursement Strategy to expand its Reimbursement, Health Economics, and Market Access (RHEMA) Division. McDermott brings 30 years of industry experience, having previously served as Vice President at Covance and held positions at Hill-Rom and Amgen. This move aims to strengthen MCRA's integrated approach to product development and commercialization for its global client base.